Bank of New York Mellon Corp Sells 4,739 Shares of Masimo Co. (NASDAQ:MASI)

Bank of New York Mellon Corp reduced its position in Masimo Co. (NASDAQ:MASI) by 1.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 337,221 shares of the medical equipment provider’s stock after selling 4,739 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.63% of Masimo worth $55,743,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. UMB Bank n.a. boosted its position in shares of Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 123 shares during the period. Trust Co. of Vermont bought a new position in shares of Masimo in the fourth quarter worth approximately $33,000. Blue Trust Inc. boosted its position in shares of Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares during the period. GAMMA Investing LLC boosted its position in shares of Masimo by 136.5% in the fourth quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider’s stock worth $77,000 after purchasing an additional 269 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Masimo in the third quarter worth approximately $118,000. 85.96% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on MASI. Stifel Nicolaus restated a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Piper Sandler upped their target price on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Raymond James upped their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Finally, Wells Fargo & Company upped their target price on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Price Performance

MASI stock opened at $183.46 on Wednesday. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company has a fifty day simple moving average of $174.43 and a two-hundred day simple moving average of $155.05. The firm has a market capitalization of $9.90 billion, a P/E ratio of 126.52 and a beta of 1.02.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.